Insilico rentosertib makes six proteomic aging clocks trend younger in IPF trial
A Nature Biotechnology analysis of 42 rentosertib-treated IPF trial participants found younger predicted biological-age profiles across six proteomic clocks, but researchers caution that the finding does not prove human aging was reversed.